pregabalin zentiva
zentiva, k.s. - pregabalin - anxiety disorders; epilepsy - antiepileptics, - neuropathic pain , pregabalin zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , epilepsy , pregabalin zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , generalised anxiety disorder , pregabalin zentiva is indicated for the treatment of generalised anxiety disorder (gad) in adults.
prepandrix
glaxosmithkline biologicals s.a. - a / indonesia / 05/2005 (h5n1) som brukt belastning (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vaksiner - aktiv immunisering mot h5n1 subtype av influensa-a-virus. denne indikatoren er basert på immunogenicity data fra friske personer fra fylte 18 år fremover etter administrering av to doser av vaksinen forberedt med subtype h5n1 stammer. prepandrix bør brukes i samsvar med offisielle veiledning.
anoro ellipta 55 mikrog / 22 mikrog
farmagon - umeklidiniumbromid / vilanteroltrifenatat - inhalasjonspulver, dosedispensert - 55 mikrog / 22 mikrog
anoro 55 mikrog / 22 mikrog
orifarm as - umeklidinium / vilanterol - inhalasjonspulver, dosedispensert - 55 mikrog / 22 mikrog
incruse ellipta 55 mikrog
farmagon - umeklidiniumbromid - inhalasjonspulver, dosedispensert - 55 mikrog
latuda 18.5 mg
2care4 aps - lurasidonhydroklorid - tablett, filmdrasjert - 18.5 mg
latuda 37 mg
orifarm as - lurasidonhydroklorid - tablett, filmdrasjert - 37 mg
latuda 37 mg
2care4 aps - lurasidonhydroklorid - tablett, filmdrasjert - 37 mg
latuda 74 mg
2care4 aps - lurasidonhydroklorid - tablett, filmdrasjert - 74 mg
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiske midler - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.